Trump announces

Cnn
–

President Donald Trump announced on Sunday that he plans to resume a controversial policy from his first term that aims to reduce the drug costs by relying payments for certain medication on your prices in other countries.

His previous rule, which was referred to as the “most preferred nation”, was completed at the end of 2020, but was blocked by federal courts and canceled by the then President Joe Biden in 2021. It would have applied for certain medicines that were administered in the medical offices for medical payments. However, it is unclear which payments or medication the new guideline applies.

In a social post on Sunday evening in the trump, Trump said that he was planning to sign an executive regulation on Monday morning, which he argues that he would drastically reduce drug prices.

“I will sign one of the most advanced management orders in our country's history. Prescription medication and drug prices are almost immediately reduced by 30% to 80%,” he wrote. “I will set up a most preferred national policy in which the United States pay the same price as the nation that pays the lowest price all over the world.”

The guideline comes when the Trump administration also tries to impose tariffs for pharmaceutical imports that were freed from the levies that were issued during the first term of the president. The tariffs could tighten the bottlenecks of certain medication, especially generics, and finally increase prices.

If the new executive order is comparable to the Rule 2020, both Medicare and its favored savings could be followed. However, experts said that it could also limit the patient's access to medication. A lot depends on how the directive is structured.

Although the reduction in drug prices was an essential indication of his first government, Trump did not focus on the topic in this term. And last year, politico announced his campaign that he had decided on the “favorite nation” model, which emphasized many Republicans.

The administration recently revived the idea as a potential way to achieve deep spending cuts for Medicaid in the House GOP taxes and expenses. However, it is unclear whether the proposal is included in the legislation, the details of which should be announced shortly or whether it is covered by the Executive Ordinance.

The initiative will probably be exposed to strong opposition from the pharmaceutical industry, which successfully continued the first iteration.

The Trump administration introduced the idea to bind Medicare's medication refunds to prices in other countries in 2018 and to have completed the rule shortly after the 2020 elections. The seven-year model would have made it possible for the United States to enable discounts that were negotiated by other peer countries to make a pork backback, which is usually largely less for medication, since their governments often determine the costs.

As part of the 2020 initiative, Medicare would have paid the lowest price for the lowest price for 50 part -B medication that is administered in medical agencies. The administration estimated that it would have saved about 86 billion US dollars.

At that time, Medicare was excluded from the negotiation of pharmaceutical prices, but this changed with the adoption of the Inflation Reducation Act of 2022, which Medicare gave historical power to negotiate prices for a small number of medication annually.

A “most preferred nation” or proposal could save the money of the beneficiaries in their expense and premiums, both of whom are affected by the drug price, said experts.